unknown
Stage
2020
Founded
2
Investors
About
Guardian Bio develops a proprietary process to generate true cDC1 dendritic cells from patients’ stem cells to restore antigen presentation and enhance anti-cancer immunity in late stage solid tumor patients.
Explore Guardian Bio's full profile on Brouky
Funding rounds, investor list, and risk signals — unlock with a subscription.